Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consolidative Radiotherapy in Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma
NCT04248452Phase 3Active, not recruiting
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- May 2020
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in esophageal adenocarcinoma (EAC) and gastric adenocarcinoma (6 arms), sponsored by ECOG-ACRIN Cancer Research Group. Primary endpoint: Overall Survival at 5 years. Started May 2020; status: active, not recruiting.
02
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04248452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04248452.